# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-126793
Filing Date
2024-11-14
Accepted
2024-11-14 09:30:30
Documents
40
Period of Report
2024-09-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | tcrt-20240930.htm iXBRL | 10-Q | 1382281
2 | EX-31.1 | tcrt-ex31_1.htm | EX-31.1 | 13631
3 | EX-32.1 | tcrt-ex32_1.htm | EX-32.1 | 7299
| Complete submission text file | 0000950170-24-126793.txt |  | 4231878

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | tcrt-20240930.xsd | EX-101.SCH | 610502
42 | EXTRACTED XBRL INSTANCE DOCUMENT | tcrt-20240930_htm.xml | XML | 446312

Mailing Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 225 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 241457791
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)